|
|
Vaccine Detail
|
Herpes Simplex Virus 2 DNA Vaccine Vaxfectin-gD2 |
| Vaccine Information |
- Vaccine Name: Herpes Simplex Virus 2 DNA Vaccine Vaxfectin-gD2
- Target Pathogen: Herpes simplex virus type 1 and 2
- Target Disease: Herpes
- Vaccine Ontology ID: VO_0004521
- Type: DNA vaccine
- Status: Research
- gD
gene engineering:
- Type: DNA vaccine construction
- Description:
- Detailed Gene Information: Click Here.
- DNA vaccine plasmid:
- DNA vaccine plasmid name:
- DNA vaccine plasmid VO ID: VO_0000334
- Immunization Route: Intravaginal injection
|
| Host Response |
|
Mouse Response
- Vaccine Immune Response Type: VO_0000286
- Immune Response: Both FL and S forms of gD2 formulated with Vaxfectin showed significantly higher antibody titres, compared with gD2 alone (Shlapobersky et al., 2012).
- Efficacy: At a high viral challenge, the 0.1 µg dose of FL gD2 Vaxfectin-formulated pDNA yielded 80 % survival. In addition, 40 % of mice vaccinated with adjuvanted FL pDNA had no detectable HSV-2 viral genomes in the dorsal root ganglia (Shlapobersky et al., 2012).
|
| References |
Shlapobersky et al., 2012: Shlapobersky M, Marshak JO, Dong L, Huang ML, Wei Q, Chu A, Rolland A, Sullivan S, Koelle DM. Vaxfectin-adjuvanted plasmid DNA vaccine improves protection and immunogenicity in a murine model of genital herpes infection. The Journal of general virology. 2012; 93(Pt 6); 1305-1315. [PubMed: 22398318].
|
|
